A $5B Pfiz­er buy­out? Am­gen, Gilead head­line M&A Thurs­day; Al­ny­lam's AT­TR sweep; An­drew Lo's rare dis­ease quest; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

One of the cool things about adding End­pointsPhar­ma to the dai­ly ros­ter is that my col­leagues can now ded­i­cate time to track­ing quar­ter­ly up­dates and tun­ing in­to calls with Big Phar­ma com­pa­nies. Check out their dis­patch from the Q2 earn­ings be­low.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.